Johnson & Johnson reported $99.3B of revenue over the trailing twelve months, +7.8% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $99.3B (to Q3 2026). Net income: $16.1B, trailing twelve months to Q3 2026. Free cash flow: $20.6B, trailing twelve months to Q3 2026. EPS: $6.59, trailing twelve months to Q3 2026.

JNJJohnson & Johnson

Healthcare

$263.86+40% 1Y

$263.86

$182.8052 weeks$278.28

JNJ as reported

Johnson & Johnson reported $99.3B of revenue over the trailing twelve months, +7.8% on the year before. 11 reported series are charted on this page, each one as filed.

$99.3B

Revenue, trailing twelve months · to Q3 2026 · +7.8% against the twelve months before

Net income: $16.1B
Net income · −36% year on year · trailing twelve months to Q3 2026
Free cash flow: $20.6B
Free cash flow · +5.1% year on year · trailing twelve months to Q3 2026
EPS: $6.59
EPS · −36% year on year · trailing twelve months to Q3 2026

Details›

Every series Ryufin has for JNJ, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$99.3B	+7.8%	Q3 2026
Net income	$16.1B	−36%	Q3 2026
EPS	$6.59	−36%	Q3 2026
Gross margin	68%	n/a	Q3 2026
Operating margin	30%	n/a	Q1 2015 · 46 quarters behind
Net margin	16%	n/a	Q3 2026
ROE	26%	n/a	Q3 2026
ROA	11%	n/a	Q3 2026
ROIC	28%	n/a	Q1 2015 · 46 quarters behind
Free cash flow	$20.6B	+5.1%	Q3 2026
P/E	40.0	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.